{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Change From Baseline in Pericardial Effusion at Month 6 and 12"
        ],
        [
            "Tafamidis",
            "0",
            ""
        ]
    ],
    "pageTitle": "The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00694161?sect=Xj0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042982745.46/warc/CC-MAIN-20150728002302-00247-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 886587023,
    "recordOffset": 886574836,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Part 1 (up to Week 6) Participant Flow for 2 periods Participants with variant transthyretin (TTR) genotype (valine replaced at position 122 by isoleucine or V122I) and wild-type TTR genotype received tafamidis (Fx-1006A) 20 milligram (mg) capsule orally once daily up to Week 6 in Part 1 and participants who achieved TTR stabilization at Week 6 continued to receive tafamidis (Fx-1006A) 20 mg capsule orally once daily up to Month 12 in Part 2. Tafamidis Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow",
    "textAfterTable": "NOT COMPLETED \u00a0 \u00a0 0 \u00a0 Period 2: \u00a0 Part 2 (After Week 6 up to Month 12) \u00a0 \u00a0 Tafamidis \u00a0 STARTED \u00a0 \u00a0 35 \u00a0 COMPLETED \u00a0 \u00a0 32 \u00a0 NOT COMPLETED \u00a0 \u00a0 3 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Physician Decision \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}